Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study-Reference-Cited by-同舟云学术

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

Published:2009-06 Issue:6 Volume:10 Page:581-588
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kaufman Bella,Trudeau Maureen,Awada Ahmad,Blackwell Kimberly,Bachelot Thomas,Salazar Vanessa,DeSilvio Michelle,Westlund Ronald,Zaks Tal,Spector Neil,Johnston Stephen

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease;Liauw;Cancer,2004

2. Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features;Boussen;Semin Oncol,2008

3. Update on the management of inflammatory breast cancer;Cristofanilli;Oncologist,2003

4. Inflammatory breast cancer: clinical progress and the main problems that must be addressed;Giordano;Breast Cancer Res,2003

5. Inflammatory breast cancer: a review;Jaiyesimi;J Clin Oncol,1992

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Blood Serum Antagonizes Effects of EGFR/HER2-Targeted Drug Lapatinib on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Биохимия;2024-09-14

2. Prognostic and therapeutic potential of STAT3: Opportunities and challenges in targeting HPV-mediated cervical carcinogenesis;Critical Reviews in Oncology/Hematology;2024-05

3. Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Biochemistry (Moscow);2024-03

4. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery;Journal of Experimental & Clinical Cancer Research;2024-01-20

5. Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer;Cancer Control;2024-01